Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.

Rojavin MA, Chapdelaine H, Tortorici MA, Praus M, Baheti G, Zhang Y, Hofmann J, Labrosse R, Dicaire R, Haddad E.

Clin Pharmacol Drug Dev. 2019 Dec 8. doi: 10.1002/cpdd.753. [Epub ahead of print]

PMID:
31814328
2.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep.

3.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26. Erratum in: Lancet Neurol. 2018 Aug;17(8):661.

4.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

PMID:
21422814
5.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.

Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019. Epub 2009 Oct 14.

PMID:
19835829
6.

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, Malzone C, Castellino F, Gentile C, McNally T, Del Giudice G, Banzhoff A, Brauer V, Montomoli E, Zambon M, Katz J, Nicholson K, Stephenson I.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7. doi: 10.1073/pnas.0903181106. Epub 2009 Apr 27.

7.

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A.

N Engl J Med. 2008 Oct 9;359(15):1631-3. doi: 10.1056/NEJMc0805274. No abstract available.

PMID:
18843132
8.

Phase I comparability of recombinant human albumin and human serum albumin.

Bosse D, Praus M, Kiessling P, Nyman L, Andresen C, Waters J, Schindel F.

J Clin Pharmacol. 2005 Jan;45(1):57-67.

PMID:
15601806
9.

The intron 6 G/T polymorphism of c-myb oncogene and the risk for coronary in-stent restenosis.

Gross CM, Krämer J, Pfeufer A, Dietz R, Gessner R, Praus M.

Basic Res Cardiol. 2004 Jul;99(4):309-14. Epub 2004 Apr 16. Erratum in: Basic Res Cardiol. 2004 Jul;99(4):315.

PMID:
15221349
10.

Prion protein stimulates tissue-type plasminogen activator-mediated plasmin generation via a lysine-binding site on kringle 2.

Epple G, Schleuning WD, Kettelgerdes G, Kottgen E, Gessner R, Praus M.

J Thromb Haemost. 2004 Jun;2(6):962-8.

11.

Ksp-cadherin is a functional cell-cell adhesion molecule related to LI-cadherin.

Wendeler MW, Praus M, Jung R, Hecking M, Metzig C, Gessner R.

Exp Cell Res. 2004 Apr 1;294(2):345-55.

PMID:
15023525
12.

Both lysine-clusters of the NH2-terminal prion-protein fragment PrP23-110 are essential for t-PA mediated plasminogen activation.

Epple G, Langfeld K, Baier M, Holzhütter HG, Schleuning WD, Köttgen E, Gessner R, Praus M.

Thromb Haemost. 2004 Mar;91(3):465-72.

PMID:
14983221
13.

Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.

Koster A, Huebler S, Merkle F, Hentschel T, Gründel M, Krabatsch T, Tambeur L, Praus M, Habazettl H, Kuebler WM, Kuppe H.

Anesth Analg. 2004 Feb;98(2):285-90, table of contents.

PMID:
14742356
14.

Stimulation of plasminogen activation by recombinant cellular prion protein is conserved in the NH2-terminal fragment PrP23-110.

Praus M, Kettelgerdes G, Baier M, Holzhütter HG, Jungblut PR, Maissen M, Epple G, Schleuning WD, Köttgen E, Aguzzi A, Gessner R.

Thromb Haemost. 2003 May;89(5):812-9.

PMID:
12719777
15.
16.

Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.

Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R, Kuppe H.

Anesthesiology. 2002 Oct;97(4):837-41.

PMID:
12357148
17.

The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.

Koster A, Despotis G, Gruendel M, Fischer T, Praus M, Kuppe H, Levy JH.

Anesth Analg. 2002 Jul;95(1):26-30, table of contents.

PMID:
12088937
18.

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.

Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noël A.

J Cell Biol. 2001 Feb 19;152(4):777-84.

19.
20.

Alert systems for post-marketing surveillance of adverse drug reactions.

Praus M, Schindel F, Fescharek R, Schwarz S.

Stat Med. 1993 Dec 30;12(24):2383-93.

PMID:
8134741
21.

A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens.

Harabacz I, Bock H, Jüngst C, Klockmann U, Praus M, Weber R.

Vaccine. 1992;10(3):145-50.

PMID:
1557929
22.

Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization.

Klockmann U, Bock HL, Kwasny H, Praus M, Cihlová V, Tomková E, Krivanec K.

Vaccine. 1991 Jan;9(1):42-6.

PMID:
2008800
23.

Two-dimensional maps in the most extended (pH 2.5-11) immobilized pH gradient interval.

Sinha PK, Praus M, Köttgen E, Gianazza E, Righetti PG.

J Biochem Biophys Methods. 1990 Jul-Aug;21(2):173-9.

PMID:
2273202

Supplemental Content

Support Center